

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**PATENT APPLICATION**

Applicant : Lan Kluwe

Application No. : Not yet assigned Confirmation No.: Not yet assigned

Filed : Concurrently Herewith

For : METHOD FOR THE DETERMINATION OF DATA FOR THE  
PREPARATION OF THE DIAGNOSIS OF PHAKOMATOSIS

Group Art Unit : Not yet assigned

Examiner : Not yet assigned

New York, New York 10020  
October 24, 2003Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants make of record the following documents, copies of which are submitted herewith:\*

**U.S. Patents**

<u>Applicant</u>	<u>Patent No.</u>	<u>Issue Date</u>
Trofatter et al.	6,077,685	June 20, 2000
Stroun et al.	5,952,170	September 14, 1999
White et al.	5,605,799	February 25, 1997

---

\* A complete Form PTO-1449 listing these documents is attached hereto.

## OTHER DOCUMENTS

M.E. Baser, et al., "Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations," Neurology, 47:1269-1277 (1996).

Irving et al., "Molecular Genetic Analysis of the Mechanism of Tumorigenesis in Acoustic Neuroma," Arch. Otolaryngol. Head Neck Surg., 119:1222-1228 (1993).

L. Kluwe, et al., "Mosaicism" in sporadic neurofibromatosis 2 patients," Human Molecular Genetics, 7(13):2051-2055 (1998).

L. Kluwe, et al., "Allelic Loss of the *NF1* Gene in NF1-Associated Plexiform Neurofibromas," Cancer Genet Cytogenet, 113:65-69 (1999).

L. Kluwe, "Loss of NF1 Allele in Schwann Cells But Not in Fibroblasts Derived From an NF1-associated Neurofibroma," Genes, Chromosomes & Cancer 24:283-285 (1999).

L. Kluwe, et al., "The parental origin of new mutations in neurofibromatosis 2," Neurogenetics, 3:17-24 (2000).

L. Kluwe, et al., "Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: A method based on tumor analysis," Genetics in Medicine, 4(1):1-4 (2001).

D.R. Lohmann, et al., "Molecular analysis and predictive testing in retinoblastoma," Ophthalmic Genetics, 16(4):135-142 (1995).

V-F Mautner, et al., "Neurofibromatosis versus schwannomatosis", Fortschritte der Neurologie Psychiatrie, 66:271-277 (1998). [Abstract only - from BIOSIS Online, Biosciences Information Services, Philadelphia, PA].

P. Riva, et al., "Characterization of a cytogenic 17q11.2 deletion in an NF1 patient with a contiguous gene syndrome," Hum Genet, 98:646-650 (1996).

M. Sainio, et al., "Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree," Neurology, 45:1314-1322 (1995).

J. Sainz, et al., "Loss of Alleles in Vestibular Schwanomas," Archives of Otolaryngology-Head & Neck Surgery, 119:1285-1288 (1993).

The 9th European Neurofibromatosis Meeting Program, April 6-8, 2001, Venice, Italy.


K. Ueki et al., "Tight Association of Loss of Merlin Expression with Loss Heterozygosity at Chromosome 22q in Sporadic Meningiomas," Cancer Res., 59:5995-5998 (1999).

Valero et al., "Linkage Disequilibrium Between Four Intragenic Polymorphic Microsatellites of the NF1 Gene and its Implications for Genetic Counselling," J. Mol. Genet., 3:590-593 (1996).

Copies of all the documents listed above were submitted by applicant in parent U.S. Patent Application No. 09/893,237 or were cited by the Examiner during prosecution of the parent application. Pursuant to 37 C.F.R. §1.98(d), applicant has not enclosed copies of the listed documents herewith. However, applicant stands ready to provide copies at the Examiner's request.

Applicants respectfully request that the above documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

Respectfully submitted,

  
Jane T. Gunnison (Reg. No. 38,479)  
Attorney for Applicants  
R. Minako Pazdera (Reg. No. 46,984)  
Agent for Applicants  
c/o FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax.: (212) 596-9090

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NNFF-1 CON	APPLN. NO. Not yet assigned
	APPLICANT Lan Kluwe	CONFIRMATION NO. Not yet assigned	
	FILING DATE Concurrently Herewith	GROUP Not yet assigned	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,077,685	06/20/00	Trofatter et al.	435	69.1	
	5,952,170	09/14/99	Stroun et al.	435	6	
	5,605,799	02/25/97	White et al.	435	6	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	M.E. Baser, et al., "Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations," <u>Neurology</u> , 47:1269-1277 (1996).
	Irving et al., "Molecular Genetic Analysis of the Mechanism of Tumorigenesis in Acoustic Neuroma," <u>Arch. Otolaryngol. Head Neck Surg.</u> , 119:1222-1228 (1993).
	L. Kluwe, et al., "Mosaicism" in sporadic neurofibromatosis 2 patients," <u>Human Molecular Genetics</u> , 7(13):2051-2055 (1998).
	L. Kluwe, et al., "Allelic Loss of the NF1 Gene in NF1-Associated Plexiform Neurofibromas," <u>Cancer Genet Cytogenet</u> , 113:65-69 (1999).
	L. Kluwe, "Loss of NF1 Allele in Schwann Cells But Not in Fibroblasts Derived From an NF1-associated Neurofibroma," <u>Genes, Chromosomes &amp; Cancer</u> , 24:283-285 (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NNFF-1 CON	APPLN. NO. Not yet assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Lan Kluwe	CONFIRMATION NO. Not yet assigned
		FILING DATE Concurrently Herewith	GROUP Not yet assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL	
	L. Kluwe, et al., "The parental origin of new mutations in neurofibromatosis 2," <u>Neurogenetics</u> , 3:17-24 (2000).
	L. Kluwe, et al., "Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: A method based on tumor analysis," <u>Genetics in Medicine</u> , 4(1):1-4 (2001).
	D.R. Lohmann, et al., "Molecular analysis and predictive testing in retinoblastoma," <u>Ophthalmic Genetics</u> , 16(4):135-142 (1995).
	V-F Mautner, et al., " Neurofibromatosis versus schwannomatosis", <u>Fortschritte der Neurologie Psychiatrie</u> , 66:271-277 (1998). [Abstract only - from BIOSIS Online, Biosciences Information Services, Philadelphia, PA].
	P. Riva, et al., "Characterization of a cytogenic 17q11.2 deletion in an NF1 patient with a contiguous gene syndrome," <u>Hum Genet</u> , 98:646-650 (1996).
	M. Sainio, et al., "Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree," <u>Neurology</u> , 45:1314-1322 (1995).
	J. Sainz, et al., "Loss of Alleles in Vestibular Schwanomas," <u>Archives of Otolaryngology-Head &amp; Neck Surgery</u> , 119:1285-1288 (1993).
	The 9th European Neurofibromatosis Meeting Program, April 6-8, 2001, Venice, Italy.
	K. Ueki et al., "Tight Association of Loss of Merlin Expression with Loss Heterozygosity at Chromosome 22q in Sporadic Meningiomas," <u>Cancer Res.</u> , 59:5995-5998 (1999).
	Valero et al., "Linkage Disequilibrium Between Four Intragenic Polymorphic Microsatellites of the NF1 Gene and its Implications for Genetic Counselling," <u>J. Mol. Genet.</u> , 3:590-593 (1996).

**EXAMINER****DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.